ANTHEM BIOSCIENCES LTD ANTHEM NIFTY_MIDNSEPHARMA
Company Overview
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.
Why Investors Should Care
Generates a return on equity of 19.4%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 26.8%.
Net profit has compounded at 15.4% per year over the last five years.
Revenue has grown at a 26.2% CAGR over the past five years.
Maintains a net profit margin of 27.9%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹2,124.33 Cr (+15.2% YoY); net profit ₹591.79 Cr.
- Trailing 12 Months Year-on-year growth — revenue +15.2%, earnings +31.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 26.2%, profit CAGR 15.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 26.20% |
| 1 Year: | 15.17% |
Compounded Profit Growth
| 5 Years: | 15.39% |
| 1 Year: | 31.14% |
Stock Price Performance
| 1 Year: | +2.96% |
| 6 Months: | +19.41% |
| 3 Months: | +3.96% |
| 1 Month: | -2.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)43.45 · Neutral
P/E of 93.34 is above the sector median of 39.70 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 26.8%.
- Excellent profit margin of 27.9%.
- Compounding revenue at 26.2% over 5 years.
- Profit CAGR of 15.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 93.3.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ANTHEM ANTHEM BIOSCIENCES LTD NIFTY_MIDNSEPHARMA | 750.00 | 93.34 | ₹42,128.54 Cr | 0.27% | 26.77% | 19.45% | 26.20% | 15.39% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,948.80 | 40.77 | ₹4.68 L Cr | 0.83% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 7,315.50 | 75.61 | ₹1.94 L Cr | 0.44% | 18.96% | 15.32% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,952.20 | 87.70 | ₹1.68 L Cr | 0.78% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,981.00 | 66.51 | ₹1.29 L Cr | 0.23% | 19.79% | 20.48% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,440.10 | 22.07 | ₹1.16 L Cr | 0.90% | 14.86% | 11.27% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,137.40 | 22.71 | ₹1.14 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,494.30 | 21.42 | ₹1.14 L Cr | 0.72% | 28.42% | 23.76% | 19.10% | 131.46% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 1,099.00 | 99.82 | ₹1.07 L Cr | 0.18% | 12.57% | 13.42% | 22.37% | 9.34% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 339.00 Cr | - | 497.81 Cr | 483.20 Cr | 540.00 Cr | 550.03 Cr | 423.15 Cr | 610.94 Cr |
| Cost of Revenue | - | - | 232.71 Cr | 176.85 Cr | - | 223.36 Cr | 142.59 Cr | 215.46 Cr |
| Gross Profit | - | - | 265.10 Cr | 306.35 Cr | - | 326.67 Cr | 280.56 Cr | 395.49 Cr |
| Operating Expenses | 218.00 Cr | - | 125.87 Cr | 141.58 Cr | 349.00 Cr | 142.26 Cr | 157.90 Cr | 167.86 Cr |
| Operating Income | 102.00 Cr | - | 139.23 Cr | 164.77 Cr | 165.00 Cr | 184.40 Cr | 122.67 Cr | 227.62 Cr |
| EBITDA | 121.00 Cr | - | 183.88 Cr | 209.25 Cr | 191.00 Cr | 266.13 Cr | 165.36 Cr | 319.41 Cr |
| Interest Expense | 4.00 Cr | - | 2.55 Cr | 52.10 L | 2.00 Cr | 3.03 Cr | 35.20 L | 1.90 Cr |
| Pretax Income | 118.00 Cr | - | 161.05 Cr | 178.31 Cr | 186.00 Cr | 229.60 Cr | 130.47 Cr | 277.92 Cr |
| Tax Provision | 35.40 Cr | - | 36.72 Cr | 95.69 Cr | 50.22 Cr | 56.17 Cr | 37.66 Cr | 88.16 Cr |
| Net Income | 82.00 Cr | - | 124.33 Cr | 82.62 Cr | 136.00 Cr | 173.43 Cr | 92.82 Cr | 189.76 Cr |
| Diluted EPS | 1.47 | - | 2.21 | 1.47 | 2.42 | 3.06 | 1.64 | 3.34 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 633.00 Cr | 1,103.00 Cr | - | 1,056.92 Cr | 1,419.37 Cr | 1,844.55 Cr | 2,124.33 Cr |
| Cost of Revenue | - | - | - | 339.28 Cr | 599.55 Cr | 743.91 Cr | 812.28 Cr |
| Gross Profit | - | - | - | 717.65 Cr | 819.82 Cr | 1,100.64 Cr | 1,312.05 Cr |
| Operating Expenses | 451.00 Cr | 695.00 Cr | - | 345.95 Cr | 395.19 Cr | 508.49 Cr | 606.79 Cr |
| Operating Income | 120.00 Cr | 346.00 Cr | - | 371.70 Cr | 424.63 Cr | 592.15 Cr | 705.26 Cr |
| EBITDA | 182.00 Cr | 408.00 Cr | - | 569.27 Cr | 568.42 Cr | 756.25 Cr | 964.85 Cr |
| Interest Expense | 20.00 Cr | 17.00 Cr | - | 8.20 Cr | 9.28 Cr | 10.02 Cr | 6.54 Cr |
| Pretax Income | 121.00 Cr | 366.00 Cr | - | 497.30 Cr | 477.32 Cr | 656.87 Cr | 824.24 Cr |
| Tax Provision | 27.83 Cr | 95.16 Cr | - | 112.11 Cr | 110.01 Cr | 205.61 Cr | 232.45 Cr |
| Net Income | 93.00 Cr | 271.00 Cr | - | 385.19 Cr | 367.31 Cr | 451.26 Cr | 591.79 Cr |
| Diluted EPS | 110.62 | 319.74 | 7.22 | 6.86 | 6.54 | 8.04 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Total Assets | 787.00 Cr | 1,034.00 Cr | - | 2,014.46 Cr | 2,398.11 Cr | 2,807.58 Cr | 3,429.29 Cr |
| Current Assets | - | - | - | 1,323.17 Cr | 1,481.55 Cr | 1,488.17 Cr | 1,803.14 Cr |
| Cash & Equivalents | - | - | - | 342.24 Cr | 183.86 Cr | 171.44 Cr | 272.91 Cr |
| Inventory | - | - | - | 129.42 Cr | 211.35 Cr | 340.43 Cr | 124.52 Cr |
| Receivables | - | - | - | 274.07 Cr | 490.45 Cr | 450.40 Cr | 590.59 Cr |
| Total Liabilities | - | - | - | 273.79 Cr | 473.46 Cr | 397.72 Cr | 386.77 Cr |
| Current Liabilities | - | - | - | 163.87 Cr | 338.63 Cr | 326.23 Cr | 325.71 Cr |
| Long Term Debt | - | - | - | 96.19 Cr | 111.66 Cr | 47.03 Cr | 27.73 Cr |
| Total Debt | 159.00 Cr | 100.00 Cr | - | 126.15 Cr | 238.52 Cr | 113.32 Cr | 53.92 Cr |
| Total Equity | 421.00 Cr | 701.00 Cr | - | 1,740.67 Cr | 1,924.65 Cr | 2,409.86 Cr | 3,042.52 Cr |
| Shares Outstanding | - | - | - | 56.16 Cr | 56.16 Cr | 56.16 Cr | 56.17 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 166.00 Cr | 278.00 Cr | - | 305.99 Cr | 140.15 Cr | 270.55 Cr | 844.49 Cr |
| Investing Cash Flow | -109.00 Cr | -196.00 Cr | - | -376.02 Cr | -221.46 Cr | -146.56 Cr | -701.62 Cr |
| Financing Cash Flow | -48.00 Cr | -63.00 Cr | - | 63.97 Cr | -77.18 Cr | -135.65 Cr | -40.00 Cr |
| Capital Expenditure | -47.00 Cr | -119.00 Cr | - | -194.55 Cr | -297.19 Cr | -261.21 Cr | -211.17 Cr |
| Free Cash Flow | 119.00 Cr | 159.00 Cr | - | 111.44 Cr | -157.03 Cr | 9.34 Cr | 633.32 Cr |
| Net Change in Cash | 9.00 Cr | 18.00 Cr | - | -6.06 Cr | -158.49 Cr | -11.66 Cr | 102.87 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 67.9% | 57.8% | 59.7% | 61.8% |
| Operating Margin % | 19.0% | 31.4% | - | 35.2% | 29.9% | 32.1% | 33.2% |
| Net Margin % | 14.7% | 24.6% | - | 36.4% | 25.9% | 24.5% | 27.9% |
| ROE % | 22.1% | 38.7% | - | 22.1% | 19.1% | 18.7% | 19.5% |
| ROCE % | - | - | - | 20.1% | 20.6% | 23.9% | 22.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANTHEM
Anthem Biosciences Ltd (NSE:ANTHEM) Q4 2026 Earnings Call Highlights: Record Growth and ...
Anthem Biosciences Ltd (NSE:ANTHEM) reports robust financial performance with significant revenue growth and strategic investments for future capacity expansion.
Anthem Biosciences Ltd (NSE:ANTHEM) Q3 2025 Earnings Call Highlights: Strong EBITDA Growth ...
Anthem Biosciences Ltd (NSE:ANTHEM) reports robust EBITDA margins and strategic growth plans despite facing market challenges and exceptional costs.
ANTHEM — Frequently Asked Questions
What is the current share price of ANTHEM BIOSCIENCES LTD (ANTHEM)?
As of 2026-07-16 05:21 IST, ANTHEM BIOSCIENCES LTD (ANTHEM) trades at ₹750.00 on NSE. Its 52-week range is ₹590.86 to ₹862.25.
What is the market capitalisation of ANTHEM?
ANTHEM BIOSCIENCES LTD (ANTHEM) has a market capitalisation of ₹42,128.54 Cr on NSE.
What is the P/E ratio of ANTHEM?
ANTHEM trades at a trailing price-to-earnings (P/E) ratio of 93.34. The industry average P/E is 39.70. Its price-to-book (P/B) ratio is 13.80.
Does ANTHEM pay a dividend?
ANTHEM BIOSCIENCES LTD (ANTHEM) currently offers a dividend yield of 0.27%.
What is the return on equity (ROE) of ANTHEM?
ANTHEM has a return on equity (ROE) of 19.45%. Its return on capital employed (ROCE) is 26.77%.
Is ANTHEM a good stock to buy?
This page provides a data-driven analysis of ANTHEM BIOSCIENCES LTD (ANTHEM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.